ACTRIMS–ECTRIMS 2026 at a glance
The joint ACTRIMS–ECTRIMS 2026 meeting in Toronto highlights emerging developments in multiple sclerosis (MS) and neuroimmunology, with particular attention to treatment differentiation beyond relapse control.
Key themes include BTK inhibitors, CAR T-cell therapies, progression biomarkers and treatment strategies for NMOSD and MOGAD. Artificial intelligence and digital biomarkers also feature in discussions around disease monitoring and treatment decision support.
📅 Build your schedule around the topics that matter most.
📥 Download the ACTRIMS-ECTRIMS_2026_Preview_by_LucidQuest
Multiple Sclerosis Therapies at ECTRIMS–ACTRIMS 2026
BTK Inhibitors Differentiation in MS Treatment
Fenebrutinib, remibrutinib and tolebrutinib data will test distinctions in efficacy, CNS penetration and progression-related outcomes.
CAR T-Cell Therapy and Immune Reset in MS
Zola-cel and allogeneic CD19 CAR T (TG-Azercel-101) will bring emerging safety and efficacy evidence into focus.
MS Progression Biology and Biomarkers
PIRA, paramagnetic rim lesions and slowly expanding lesions may help redefine how treatment effects are measured.
NMOSD and MOGAD Treatment Strategies
METEOROID, TOMATO and EASE-NMO could inform treatment segmentation, sequencing and acute-attack strategies.
Competitor and Industry Signals at ACTRIMS–ECTRIMS 2026: New MS Therapies
Roche
FENhance/FENtrepid, OCARINA II and satralizumab will support discussions around BTK inhibition, anti-CD20 delivery and rare neuroimmunology.
Sanofi
Tolebrutinib HERCULES outcomes and frexalimab development will focus attention on non-relapsing progression.
Novartis
Early high-efficacy therapy, ofatumumab and BTK inhibition will feature in treatment positioning discussions.
Emerging MS Therapies: Obexelimab, Orelabrutinib and CAR T
Zenas BioPharma’s obexelimab and orelabrutinib, alongside new CAR T programmes, will add competitive dimensions.
Artificial Intelligence and Machine Learning at ACTRIMS–ECTRIMS 2026
AI-Assisted MRI
A randomised clinical trial will examine AI-supported detection of MS disease activity.
Predictive Models
ML and smartphone-derived measures will explore PIRA prediction, progression monitoring and treatment decision support.
What to Watch After ACTRIMS–ECTRIMS 2026
- Whether BTK inhibitors demonstrate meaningful clinical and biomarker differentiation.
- Whether CAR T durability and neurotoxicity support broader clinical use.
- Whether AI and digital biomarkers advance toward validated, routine monitoring.
Download LucidQuest’s ACTRIMS–ECTRIMS 2026 Preview Report
Download our ACTRIMS–ECTRIMS 2026 preview report for deeper analysis of emerging MS therapies, treatment differentiation, progression biomarkers, competitor positioning and AI applications in neuroimmunology.
📅 Build your schedule around the sessions that matter most.
📥 Download the ACTRIMS-ECTRIMS_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
